All In Biotech

Drug Trial Radar · NCT07184619

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 23, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Newron Pharmaceuticals SPAIndustry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.

Conditions

  • Treatment-resistant Schizophrenia

Interventions

  • Evenamide 15 mg bidDrug

    Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment

  • PlaceboDrug

    Matching placebo capsules bid for a total of 12 weeks of add-on treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to endpoint (Week 12) on the total score of the Positive and Negative Syndrome Scale (PANSS).Time frame: From Baseline to Week 12
  2. Incidence of treatment-emergent adverse events (TEAEs), AEs leading to discontinuation (ADOs), and serious AEs (SAEs).Time frame: From Baseline to 30-day Safety Follow up (12 Weeks of treament + 30-day safety follow up)

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA DGSOM, UCLA Health, UCLA Semel Institute

    Los Angeles, California · Suspended

  • University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital

    Miami, Florida · Suspended

  • Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine

    Atlanta, Georgia · Suspended

  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine

    Baltimore, Maryland · Suspended

  • Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research

    New York, New York · Suspended

  • INSA- Instituto de Neurociencias San Agustin

    La Plata, Buenos Aires, Argentina · Recruiting

  • Global Psy Asociacion Civil

    La Plata, Buenos Aires, Argentina · Not yet recruiting

  • Fundación para el Estudio y Tratamiento de las Enfermedades Mentales

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Centro Iternova-Consultorios en Salud Mental

    Córdoba, Córdoba Province, Argentina · Not yet recruiting

  • Centro Especializado en Neurociencias (CEN)

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • CIAP-Centro de Invest y Asistencia en Psiquiatria

    Rosario, Santa Fe Province, Argentina · Recruiting

  • E.S.E. Hosp Mental de Antioquia Maria Upegui-Homo

    Bello, Antioquia, Colombia · Not yet recruiting

  • Inst Colombiano del Sistema Nervioso - ClinMontserrat

    Bogotá, Bogota D.C., Colombia · Not yet recruiting

  • Help Hospital

    Vijayawada, Andhra Pradesh, India · Recruiting

  • Gauhati Medical College and Hospital

    Guwahati, Assam, India · Recruiting

  • Masina Hospital Trust

    Mumbai, Maharashtra, India · Recruiting

  • New Manak Healthcare Hospital

    Navi Mumbai, Maharashtra, India · Recruiting

  • Ahana Hospitals LLP

    Madurai, Tamil Nadu, India · Recruiting

  • Udyan Health Care

    Lucknow, Uttar Pradesh, India · Recruiting

  • Seth Sukhlal Karnani Memorial Hospital

    Kolkata, West Bengal, India · Recruiting

  • Hospital Tuanku Fauziah

    Kangar, Malaysia · Recruiting

  • Sentosa Hospital

    Kuching, Malaysia · Recruiting

  • Sultan Abdul Halim Hospital

    Sungai Petani, Malaysia · Recruiting

  • Kuala Lumpur Hospital

    Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.